Mall PA
IPAM NOT FOR HUMANS BANNED IN TESTED SPORT
File 06 · synthetic pentapeptide growth hormone secretagogue (ghrelin-receptor agonist)

Ipamorelin

Also called: NNC 26-0161, Aib-His-D-2-Nal-D-Phe-Lys-NH2

Banned · S2Limited

Ipamorelin is a five-amino-acid synthetic peptide developed by Novo Nordisk in the 1990s that triggers growth hormone release by acting on the ghrelin receptor. It was described as the first 'selective' secretagogue because in animal tests it raised GH without raising cortisol or ACTH.

Why the gym talks about it

It is one of the most common 'GH peptides' in gym and anti-aging circles, usually discussed as a milder way to raise growth hormone, often paired with CJC-1295.

What the research actually found

  • in vitro and animal (rat, pig)Ipamorelin released GH from rat pituitary cells and in rats and pigs with potency similar to GHRP-6, without raising ACTH or cortisol in pigs even at very high doses. Source
  • human randomized trial (different use)In a phase 2 randomized trial of 114 bowel-surgery patients, IV ipamorelin was well tolerated but did not significantly speed recovery of gut function versus placebo. Source

Human evidence: limited. Human data come from pharmacology studies and one negative phase 2 surgical trial; there are no trials of ipamorelin for muscle, body composition or performance.

Tested lifters

S2.2.4 Growth Hormone Secretagogues. Ipamorelin is named; prohibited at all times.

High. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.

FDA status

Not FDA-approved; development for postoperative ileus did not lead to approval. Ipamorelin is not on FDA's interim 503A categories list (May 14, 2026 version), so it is not eligible for 503A compounding. FDA's safety-risk page notes serious adverse events, including death, reported when ipamorelin was given intravenously in a gastric-motility study.

As of 2026-10-01.

Known and theoretical risks

  • FDA cites serious adverse events, including death, in an intravenous gastric-motility study. Source
  • Raising GH and IGF-1 carries the class concerns seen with approved GH-axis drugs (fluid retention, joint pain, glucose intolerance); long-term data for ipamorelin specifically are absent. Source

Quick answers

Is Ipamorelin banned for drug-tested lifters?

S2.2.4 Growth Hormone Secretagogues. Ipamorelin is named; prohibited at all times. High. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.

Is Ipamorelin FDA approved?

Not FDA-approved; development for postoperative ileus did not lead to approval. Ipamorelin is not on FDA's interim 503A categories list (May 14, 2026 version), so it is not eligible for 503A compounding. FDA's safety-risk page notes serious adverse events, including death, reported when ipamorelin was given intravenously in a gastric-motility study.

How strong is the human evidence for Ipamorelin?

Limited. Human data come from pharmacology studies and one negative phase 2 surgical trial; there are no trials of ipamorelin for muscle, body composition or performance.

Sources

Research-use-only information file. Nothing here is medical advice or instructions for use. Not evaluated by the FDA. Talk to your doctor.

More files

Back to the basement